Member Info for Seaking1

Same here, last time I went was a long time ago played derby county 2-0 . Use to be in the middle of the Kop behind the goal about 6 rows up . Loved watching Peter Thompson dribbling. Was at the Celtic game when the Picts threw the seats onto the pitch.
I was very lucky my friend had a gold pass for Wembley so saw a few finals and semis especially the one against Everton. Keep well and stay safe 70 year old kopite the years go to quick.

It will be worth the wait. All we have to do is beat the mancs and then back into gear .
All’s gsk has to do is get the split done then I will be a happy bunny. YNWA.

No div thanks and no more investors.I would rather see the sp rise instead.

I wouldn’t want to live in asks world either , but you are being very ofhanded about Emma she’s done a great job . You wouldn’t know but she has overseen the split which will turn out to be very good for investors. Rather than just look at the sp try reading a bit about what the split means and what’s in it. Shares go up and down people whinging when they are down and on cloud nine when they are up. FUNDAMENTALS remember that word . Same with AstraZeneca debit so what that’s what companies do, which in AstraZeneca will be cut by the profits generated by the new takeover.

The other great news for 2021 besides vaccines is that prick trump will be gone. Absolutely disgusting man. Sad thing is a lot of Americans voted for him or maybe for the party (I hope) He has done a lot of harm to America. Probably a KGB agent. That’s my rant for 2021. :-). :-) from now on. Hope you all make money as opposed to the bloody brokers.

Oxford biomedica is the main fill finish for the AstraZeneca Jenner vaccine and has now secured £15 million upfront and now £35million from AstraZeneca. The vaccine will like anything else start off slowly and then motor ahead over the next 3 months . Blinking brilliant scientists in this country. Well done. This government and others in the past have never backed funding fo science in this country ( unless it’s portadown) now they will after this awful pandemic.

I know there will be a lot of M&A. (Mergers & acquisitions ) this year, bumper year for some people I know. a good few will be in biopharma and A.I. Healthcare . I can see AstraZeneca scooping up Oxford biomedica. Also Abcam may well be a target . In my opinion. Hope we all make some money this year . I cannot see it being as bad a year as last. I have seen in the past that when it’s gloom and doom in the uk unemployment. the stock exchange seems to do well . Still trying to figure out why. A good chunk of my retirement life savings are now in funds in Asia as that’s were the future strong growth will be it’s just a matter of picking the right funds. Me I just go with the popular ones . As there are a lot of crap ones out there.

Antibody treatment looks very interesting. Let’s hope it works and helps save lives.

I was actually mussing about that as he’s attacked bigger companies before but maybe WWP is a bit to big for him at the moment.

Many thanks for “the drum” and happy new and safe year. :-).

Greater scientific presence in immunology by adding Alexion's innovative complement-technology platforms and strong pipeline

Dedicated rare disease unit to be headquartered in Boston

Geographical presence to be enhanced with broad coverage across primary, speciality and highly specialised care

Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio

Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend

The acquisition will be immediately core earnings-accretive and value-enhancing, and is aligned with stated capital-allocation priorities

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Dec. 12, 2020-- AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201212005016/en/

Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share.

The boards of directors of both companies have unanimously approved the acquisition. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021, and upon completion, Alexion shareholders will own c.15% of the combined company.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology. We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients."

Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said: “For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. I am incredibly proud of what our organisation has accomplished and am grateful to our employees for their contributions. This transaction marks the start of an exciting new chapter for Alexion. We bring to AstraZeneca a strong portfolio, innovative rare disease pipeline, a talented global workforce and strong manufacturing capabilities in biologics. We remain committed to continuing to serve the patients who rely on our medicines and firmly believe the combined organisation will be well positioned to accelerate i

Mr Math, brilliant reply. Some get a bit to greedy in my view. Not on purpose it’s just seeing other shares moving north and thinking you have lost out.

Happy new year . and use you brain and stay apart to all our chatters.
Obviously the dim amongst us won’t take notice. :-).

Pokrchips , a little bit of decorum please, and if a bid was made (which won’t happen) as gsk are in the middle of splitting. The sp would rocket which is what happens to any target when a bid is announced.

Well done Inkose were did you get that from. Shows how good the AstraZeneca vaccine is in comparison. Poor SAK50 will miss out though as he doesn’t trust the science.

Agreed, I think it’s just to keep the investors happy. Also the directors who usually have a good number of shares get a nice payout. :-). I’ve come across some companies that are trading at a substantial loss and still paying divs.

Yep very good interview I saw it December 15 in investors chronicle. I was looking up healthcare data companies but then thought I would just add to SMT instead. Seems a no brainier to me.

I suppose if you have bought 500k of shares cheaper the sp only has to move a bit for you to make a good profit .

:-) If I was wise I wouldn’t be on his or any other board. I would be somewhere in Asia or the pacific on an island fishing with a bottle of red/ white. I really think we all should be extremely great full (understatement ) to all the scientists who have worked very hard to get this and other vaccines out .
I’ve been doing a hell of a lot of digging over the last ten days or so to realign my portfolio and have decided to add to SMT as I think they will do and have done very well over the next year or so with my expectation of my investment going up by 30%. With no risk. I will still hold AstraZeneca and GSK as they will bounce back although I will have to wait.

Can’t have blue sky all the time. Its like GSK I have both losing sp value. So what, I’m not selling and I know unless we are hit by an asteroid the shares will go up at some stage.